Interestingly, in-vivo anti-tumor function of pmel-I and OT-1/2 T cells was improved by CTLA-4:CD28 expression, but was highly dependent on the presence of CD4+ T cells, and was linked to their elevated production of IL-2 [217]. This evidence concerns the gene CD28 and neoplasm.